J clin oncol. 2010 28 27 : 4184-90
WebJ Clin Oncol. 2010;28(20):3239–3247. 53. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or … WebApr 13, 2024 · We conducted a nationwide, matched case–control study of maternal/pregnancy outcomes including pre-eclampsia and Cesarean delivery (C-section) as well as neonatal outcomes including preterm birth among 207 births in women with early-onset colorectal cancer (ages 18–49) and 1019 births in women without colorectal cancer …
J clin oncol. 2010 28 27 : 4184-90
Did you know?
WebApr 11, 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be determined. Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal treatment options for recurrent platinum-resistant ovarian cancer.MethodsPubmed, … WebAug 18, 2024 · J Clin Oncol. 2010;28(27):4184–90. CrossRef PubMed PubMed Central Google Scholar Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2024;38(2):155–65.
WebJul 26, 2010 · Volume 28, Issue 27 > ORIGINAL REPORTS Hematologic Malignancies DOI: 10.1200/JCO.2010.28.1618 Journal of Clinical Oncology - published online before print … WebFilter issues by Issue archive. 2024 - Volume 41. 2024 - Volume 40. 2024 - Volume 39. 2024 - Volume 38. 2010 - 2024. 2000 - 2009. 1990 - 1999. 1980 - 1989.
WebMay 1, 2010 · J Clin Oncol. 2010 May 1;28(13):2181-90. doi: 10.1200/JCO.2009.26.2543. Epub 2010 Mar 29. Authors Anne Aupérin 1 , Cecile Le Péchoux, Estelle Rolland, Walter J Curran, Kiyoyuki Furuse, Pierre Fournel, Jose Belderbos, Gerald Clamon, Hakki Cuneyt Ulutin, Rebecca Paulus ... WebNov 22, 2016 · It is indicated for the treatment of adult patients with multiple relapsed or refractory aggressive NHL and this recommendation is reflected in national/international treatment guidelines such as the European Society of Medical Oncology (ESMO) 2 and National Institute for Health and Care Excellence (NICE) guidance in the UK. 3 The use of …
Web2 days ago · 1.Introduction 1.1.Immunotherapy for head and neck neoplasms. Head and neck neoplasms are the sixth most common malignant tumors in the world, with approximately 830,000 patients developing head and neck neoplasms each year [1].It is a general term for a class of cancers with a similar incidence and treatment plan, including …
WebComplications occurring either within 30 or 90 days of surgery were classified using the Clavien-Dindo scale ... 26, 27, 28 Adjuvant chemotherapy in this study was associated with improved OS for T3 and T4 disease but not for RFS, ... J Clin Oncol, 40 (2024), pp. 2048-2057. CrossRef View in Scopus Google Scholar. 10. crosby delivery officeWebThe study by Goldschmidt and colleagues included 81 patients with relapsed DLBCL, which occurred mostly in the first year after completion of therapy. 16 They found that stage, B symptoms, and prognostic score did not affect the way in which the relapse was detected (clinically vs by routine imaging), but extranodal involvement and timing of … crosby demolitionWebJ Clin Oncol. 1999;17:3776–3785. 4. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–4190. 5. bugalugs dog productsWebNov 8, 2011 · DLBCL is a curable disease and combination of monoclonal antibody against CD20 (rituximab) with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen have improved the prognosis of patients with a 20% increase of the cure rate. bug alt tab windows 11WebNov 3, 2016 · Submitted April 28, 2009; accepted June 12, 2009; published online ahead of print at www.jco.org on October 5, 2009. Authors’ disclosures of potential con-flicts of interest and author contribu-tions are found at the end of this article. Corresponding author: Motoko Yamaguchi, MD, PhD, Department of Hematology and Oncology, Mie Univer- crosby decorators yorkWebMay 15, 2004 · Three of the 28 responding patients did not undergo ASCT: 1 patient refused, one patient did not have an adequate number of mobilized stem cells and underwent allogeneic transplantation from his HLA-matched sibling, and one patient, who did not have any mobilized PBPCs even after a repeated attempt with G-CSF alone, was found to have … bugambilias adult day care brownsvilleWeb合肥复发难治治疗.ppt,毒副反应 Crump M, et al. J Clin Oncol 2014;32:3490 第二十九页，共六十六页，2024年，8月28日 美罗华在移植动员中的净化作用：大剂量美罗华+BEAM 移植动员方案 利妥昔单抗：动员化疗前1天，375mg/m2 静脉给药，化疗后7天，1000mg/m2 静脉给药， 移植后d1和d8， 1000mg/m2 静脉给药。 bugalugs tear stain remover